Advair Generic Approval Uncertain Despite US FDA Denial Of Sandoz Petition
Executive Summary
Agency declined to say whether ANDA sponsors would need to meet requirements requested by Sandoz; Mylan's generic user fee date is March 28.
You may also be interested in...
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.
Sandoz US President Peter Goldschmidt Talks Generic Policy Improvements
The US is behind other markets when it comes to complex generics and biosimilars, Goldschmidt said, though he is hopeful new FDA Commissioner Gottlieb and the new administration will explore ways to make approval of hard-to-replicate drugs faster.